2022
TCR gene segment usage and HLA alleles that are associated with cancer survival rates also represent racial disparities
Angelakakis G, Serraneau K, Barker V, Callahan B, Tong W, Zaman S, Huda T, Blanck G. TCR gene segment usage and HLA alleles that are associated with cancer survival rates also represent racial disparities. International Journal Of Immunogenetics 2022, 50: 41-47. PMID: 36585798, DOI: 10.1111/iji.12610.Peer-Reviewed Original ResearchConceptsTCR gene segment usageHLA allele combinationsGene segment usageCancer outcomesRacial disparitiesSegment usageHLA allelesCertain HLA allelesCancer survival ratesDistinct survival outcomesSocioeconomic factorsDisease courseSurvival outcomesInfectious disease courseSurvival rateAllele combinationsDifferent racial groupsGenetic polymorphismsPrevious pathogen exposurePathogen exposureOutcomesRacial groupsDisparitiesFactorsCancer
2020
Unproductive T cell receptor-β and T cell receptor-δ recombination recoveries in tissue and blood samples are associated with improved survival outcomes for uterine and ovarian cancers
Zaman S, Koohestani D, Diviney A, Chobrutskiy B, Arndt M. Unproductive T cell receptor-β and T cell receptor-δ recombination recoveries in tissue and blood samples are associated with improved survival outcomes for uterine and ovarian cancers. Gynecologic Oncology 2020, 159: 204. DOI: 10.1016/j.ygyno.2020.05.327.Peer-Reviewed Original ResearchImmunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members
Diaz MJ, Chobrutskiy BI, Zaman S, Blanck G. Immunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members. Cancer Treatment And Research Communications 2020, 24: 100196. PMID: 32769037, DOI: 10.1016/j.ctarc.2020.100196.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAftercareAntineoplastic Agents, ImmunologicalBiomarkers, TumorButyrophilinsColorectal NeoplasmsComplementarity Determining RegionsComputational BiologyDisease-Free SurvivalExomeGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateReceptors, Antigen, B-CellReceptors, Antigen, T-CellRecombination, GeneticRNA-SeqSurvival RateConceptsSurvival rateLung cancerColon cancerImmune receptor recombinationsWorse survival rateCancer survival ratesCases of melanomaBetter survival rateB cell receptorFamily membersSurvival distinctionsCancer Genome AtlasImmunotherapy approachesColorectal adenocarcinomaT cellsImmunogenomics studiesCancer typesCancerConsistent associationHigh expressionGenome AtlasImmune receptorsImmunogenomic featuresMelanomaCancer exomesAntiviral T Cell Receptor Complementarity Determining Region-3 Sequences Are Associated with a Worse Cancer Outcome: A Pancancer Analysis
Zaman S, Chobrutskiy BI, Patel JS, Diviney A, Tu YN, Tong WL, Gill T, Blanck G. Antiviral T Cell Receptor Complementarity Determining Region-3 Sequences Are Associated with a Worse Cancer Outcome: A Pancancer Analysis. Viral Immunology 2020, 33: 404-412. PMID: 32315578, DOI: 10.1089/vim.2019.0156.Peer-Reviewed Original ResearchConceptsT cellsRegion 3 sequencesSurvival rateTissue-resident T cellsCancer typesImmune receptor recombinationsResident T cellsWorse survival rateHuman papilloma virusWorse cancer outcomesTCGA data setsThymus cancerCancer Genome AtlasViral etiologyCancer outcomesDistinct survival ratesNeck cancerPapilloma virusDifferent cancer typesSolid tumorsTumor samplesExome filesGenome AtlasPancancer AnalysisCancer
2019
An age-based, RNA expression paradigm for survival biomarker identification for pediatric neuroblastoma and acute lymphoblastic leukemia
Diviney A, Chobrutskiy BI, Zaman S, Blanck G. An age-based, RNA expression paradigm for survival biomarker identification for pediatric neuroblastoma and acute lymphoblastic leukemia. Cancer Cell International 2019, 19: 73. PMID: 30962767, PMCID: PMC6438000, DOI: 10.1186/s12935-019-0790-5.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaOlder diagnostic ageDiagnostic agePediatric neuroblastomaLymphoblastic leukemiaPrevalent pediatric cancerCancer survival ratesAge of diagnosisYounger patientsSurvival differencesPediatric cancerHigh levelsPatientsNeuroblastomaSurvival rateGene expression markersAgeExpression markersLeukemiaSurvival metricsBiomarker identificationLevelsCancerDiseaseGenesTargeting Trop-2 in solid tumors: future prospects
Zaman S, Jadid H, Denson AC, Gray JE. Targeting Trop-2 in solid tumors: future prospects. OncoTargets And Therapy 2019, 12: 1781-1790. PMID: 30881031, PMCID: PMC6402435, DOI: 10.2147/ott.s162447.Peer-Reviewed Original ResearchAntibody-drug conjugatesTrop-2Clinical benefitClinical trialsTumor typesPlatinum-resistant urothelial cancerSmall cell lung cancerMultiple early-phase clinical trialsTriple-negative breast cancerEarly phase clinical trialsLimited treatment optionsTrop-2 expressionMultiple tumor typesUrothelial cancerTreatment optionsLung cancerBreast cancerSolid tumorsBaseline levelsCancer typesClinical useUpregulated expressionCancerTumorsNormal cells
2018
T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer
Chobrutskiy BI, Zaman S, Diviney A, Mihyu MM, Blanck G. T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer. Journal Of Cancer Research And Clinical Oncology 2018, 145: 615-623. PMID: 30539280, DOI: 10.1007/s00432-018-2815-1.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesT cell responsesBladder tumor tissuesT-cell featuresEx vivo amplificationT cell receptorBladder cancerCancer findingsFavorable outcomeCancer settingBetter outcomesSurvival rateTumor tissueCancerDriver mutationsImmunotherapyBiochemical featuresBioinformatics assessmentOutcomesAntigen bindingRegion 3TILsPatientsLymphocytesTherapyMAPT (Tau) expression is a biomarker for an increased rate of survival for low-grade glioma
Zaman S, Chobrutskiy BI, Sikaria D, Blanck G. MAPT (Tau) expression is a biomarker for an increased rate of survival for low-grade glioma. Oncology Reports 2018, 41: 1359-1366. PMID: 30535461, DOI: 10.3892/or.2018.6896.Peer-Reviewed Original ResearchMAPT expressionSurvival rateΑ-synuclein gene expressionDisease-free survivalCentral nervous systemLow-grade gliomasAssociation of MAPTRate of survivalCancer Genome AtlasBreast cancerNeurodegenerative roleTau expressionBrain cancerNervous systemNeurological disordersTau proteinMAPT geneHigh expressionCancerGenome AtlasPrecursor proteinExpression levelsSuch associationsSurvivalTauClinical Observation of Improved Outcomes of Patients With BRCA 1/2 Breast Cancer Treated With Everolimus Prior to DNA-Damaging Therapy.
Anderson M, Denson A, Zaman S, Han H, Soliman H. Clinical Observation of Improved Outcomes of Patients With BRCA 1/2 Breast Cancer Treated With Everolimus Prior to DNA-Damaging Therapy. JCO Precision Oncology 2018, 2: 1-5. PMID: 35135142, DOI: 10.1200/po.18.00123.Peer-Reviewed Original Research